SUMMARY A double-blind placebo-controlled trial of carbenoxolone, as 50 mg Duogastrone capsules, and in a dose of 200 mg daily for 12 weeks, was carried out in 40 ambulant subjects with endoscopically diganosed duodenal ulceration, of whom 34 were available for final analysis. Each patient was seen every two weeks and endoscoped at four, eight and 12 weeks. Serum carbenoxolone was measured at each visit. Complete ulcer healing occurred in a significantly greater number of patients receiving Duogastrone than placebo, the significance being greater after four and eight weeks treatment (P < 0 01) than at 12 weeks (P < 0 02). While significant symptomatic improvement also was achieved (P < 0-05), but only after 12 weeks on Duogastrone, there was much closer correlation between ulcer healing and symptom relief, 69 % on Duogastrone returning to normal, compared with 22 % of controls (P < 0-02). Rise of systolic blood pressure and reduction in serum potassium levels, especially during the last four treatment weeks, were the most common effects noted in patients taking Duogastrone, and five patients required thiazide diuretics and potassium supplements. Higher serum carbenoxolone levels were found in patients with healed ulcers as well as in those with more marked side-effects.
While several trials have shown that carbenoxolone sodium, in capsule form (Duogastrone), improves the rate of healing of duodenal ulcers (Hunt, 1968; Brown et al., 1972; Archambault et al., 1975; Gheorghiu et al., 1975) , others have given equivocal results (Colin-Jones et al., 1968; Cliff and MiltonThompson, 1970) . Symptomatic improvement has correlated poorly with duodenal ulcer healing (Brown et al., 1972) resulting in a difference of opinion about the value of Duogastrone for symptom relief, only Cliff (1968) and Hunt (1970) reporting a beneficial response.
However, as all these studies have certain shortcomings, the need for a carefully controlled trial avoiding these was evident. This report presents the results of a prolonged double-blind placebocontrolled trial, based on endoscopic assessment, of carbenoxolone sodium (Duogastrone) in the treatment of duodenal ulcers.
Methods
Patients under the age of 75 years and without 'Address for communications: Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 OHS. Received for publication 1 September 1976 cardiac, renal, or hepatic disease qualified for entry into the trial if they had symptoms of peptic ulcer disease for at least one month and if a duodenal ulcer was seen at endoscopy. Patients were excluded if there was evidence of oesophagitis, gastric ulcer, carcinoma, or gall bladder disease.
All patients were examined with a fowardviewing GIF-D Olympus fibrescope, and, in one patient in whom this did not enable adequate inspection of the duodenum, a side-viewing JF-B Olympus duodenoscope was also used. Informed consent was obtained.
Every patient was questioned, weighed, examined, and had blood drawn for haematological and biochemical investigations, which included measurement of serum electrolytes and enzymes. Each patient had an electrocardiograph, radiograph of the chest, and urinalysis. Those who had not been examined radiologically within the preceding month had a barium meal and, if gall bladder disease was suspected, a cholecystogram. Blood was drawn at each visit for measurement of serum carbenoxolone (Rhodes and Wright, 1974) .
The capsules were of identical appearance and contained either 50 mg carbenoxolone sodium (Duogastrone) or inert ingredients (placebo). Patients were instructed to swallow whole one capsule 30 minutes before each of three meals and before retiring at night, taking a total of 200 mg carbenoxolone sodium daily. Treatment was allocated randomly, according to a code known only to the hospital pharmacist and Biorex Laboratories. Each patient was also given magnesium trisilicate compound tablets (BPC) to be taken as necessary for relief of symptoms.
Medication was started within seven days of panendoscopy and was taken for 12 consecutive weeks. Assessments were made every two weeks and duodenoscopy repeated at four, eight, and 12 weeks. Patients were asked to remain ambulant and not to modify their daily habits except to take regular meals. Consistent capsule taking was emphasised; those who missed more than the equivalent of two days of medication in each week were excluded from the final analysis. At every visit patients were questioned about dietary and smoking habits, symptoms, and antacids used; they were examined, weighed, and blood pressure recorded. Symptomatic response was determined according to a grading system outlined in Table 1 . at least half the patients. In those treated with Duogastrone the correlation became more pronounced with increasing length of treatment, being most marked at 12 weeks when 11 of 16 patients (69%) had a healed ulcer and were symptom-free. In contrast only four of 18 controls (22%) had a similar response (p < 0-02). tlnitial serum potassium <3 7 mmol/l.
SIDE-EFFECTS
The side-effects in both groups 
Potassium loss
In the Duogastrone group the mean serum potassium level fell to 3-6 mmo/l at four and eight weeks and 3 0 mmol/l at 12 weeks. It was below 3-7 mmol/l in 12 Duogastrone patients during the trial (falling below 3 0 mmol/l in six), compared with only three in the placebo group. Serum bicarbonate levels rose in six patients on Duogastrone and in two controls. Four Duogastrone patients also had muscle enzyme abnormalities with elevated creatine phosphokinase (CPK) levels, of whom two had clinical muscle weakness, one requiring hospital admission at 12 weeks to correct severe hypokalaemia (1 6 mmol/l).
Potassium supplement, in the form of Slow-K tablets, was given to five patients taking Duogastrone-two during the first four weeks, two during the second four weeks and one during the last four-week period of the trial.
Hepatic enzyme abnormalities
Transient small rises in the serum alanine aminotransferase (SGPT) level occurred in two patients on Duogastrone. Other liver function tests were all normal in every patient.
SERUM CARBENOXOLONE LEVELS
There was a wide range of serum carbenoxolone concentration (1-140 ,tg/ml), as well as considerable individual variation among the 16 Duogastrone patients throughout the 12-week trial (means 6-82 ,ug/ml). Though there were too few patients for statistical analysis, a pattern did emerge. Higher carbenoxolone levels, especially in the later weeks of treatment, were noted in patients with healed ulcers, in all of whom blood levels exceeded 20 jug/ml.
Higher levels were also obtained in patients over the age of 60 years, in none of whom were they below 20 jig/ml.
The most severe side-effects were seen in the three patients with the highest carbenoxolone blood levels (means of 82, 82, and 55 ,tg/ml). They all required diuretic and potassium supplements, up to 96 mmol daily for several weeks, and had raised CPK and bicarbonate levels; two patients developed muscle weakness and diastolic hypertension and the third, systolic hypertension. Each was also taking other drugs; one chlorpropamide, another ibuprofen, and the third indomethacin. The next highest mean carbenoxolone blood level was only 36 ,ug/ml and the side-effects noted in other patients were minimal.
Discussion
The natural history of duodenal ulcer is characterised by spontaneous remission and intermittent pain, which makes for difficulty in evaluating specific drug treatment, especially if the study period is a short one. Furthermore, as duodenoscopy is more accurate than radiology in demonstrating duodenal ulcers, trials not employing endoscopy for diagnosis are also more likely to produce questionable results. Gheorghiu et al. (1975) relied exclusively on radiographic evidence of healing, yet Brown et al. (1972) found 28% disagreement between endoscopic and radiological findings. In our study the discrepancy was even greater, the initial radiograph failing to demonstrate 19 (58%) of the ulcers; in 11 others there was pyloroduodenal deformity and eight appeared normal radiologically.
In the published reports on Duogastrone most of the patients were treated for only four to six weeks. In the present study, however, maximum ulcer healing was achieved after eight weeks and symptom relief after 12 weeks on Duogastrone, a positive correlation between the two being most pronounced at the end of the trial period. Therefore, for maximum efficacy Duogastrone treatment should be maintained for at least eight and preferably 12 weeks.
SIDE-EFFECTS
Side-effects including electrolyte disturbances, muscle weakness, weight gain, oedema, or hypertension due to hypokalaemia and sodium retention have been noted in all previous trials with carbenoxolone but have generally been less frequent and severe with Duogastrone than with Biogastrone, used in the treatment of gastric ulcers. The side-effects noted in this study were no different. The mean serum potassium level dropped progressively during treatment with Duogastrone, below normal levels being recorded in 75% of patients, a higher percentage than in other reports. However, the five patients who required potassium supplementation were also taking thiazide diuretics because of oedema or hypertension, which probably further increased potassium loss.
It is noteworthy that the most severe side-effects, with the highest recorded serum carbenoxolone levels, were seen in the three patients taking other drugs concurrently. One was a newly diagnosed diabetic receiving chlorpropamide, in whom glycosuria may also have increased potassium excretion, the other two were taking anti-inflammatory drugs, ibuprofen and indomethacin respectively. Both of these and also chlorpropamide, like carbenoxolone, are protein bound and excreted through the bile, though to a varying extent. It is possible that by competitive protein binding they may have affected the absorption of carbenoxolone, raising its serum concentration and thereby increasing the severity of side-effects.
This study has confirmed the significant therapeutic benefits of carbenoxolone sodium (Duogastrone), both in relieving the symptoms and influencing the healing of duodenal ulcers. While side-effects were observed in a number of patients receiving Duogastrone, these were significant mainly in the elderly or when other drugs were used concurrently. The 
